Tag: finance

MONTRÉAL, 12 juin 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) est heureuse d’annoncer la nomination de Robin Deveaux au poste de premier vice-président et directeur général, Amérique du Nord. Il succède dès maintenant à Hugues Girardin, qui prendra sa retraite le 31 décembre 2025. D’ici là, M. Girardin agira à titre de conseiller - transition auprès de la direction, afin de faciliter le relais des responsabilités.  

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025

Potential strategic alliance aims to transform residential real estate accessibility and transaction efficiency through exclusive integration of MiiX’s proprietary platform across La Rosa’s network

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has entered into a share purchase agreement (the “ELOC”) with RK Capital Management LLC (“RK Capital”).

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.